Nitric oxide (NO) is a molecule of increasing interest in the medical world. NO is best known today as a potent vasodilator and is the end product of a number of orally administered drugs that collectively represented more than $60 Billion in 2009 pharmaceutical sales. NO plays an important role in regulating many aspects of human physiology:
Since NO is a regulatory molecule, different concentrations can have different effects. For example, at low concentrations NO is pro-inflammatory, while at higher concentrations it is anti-inflammatory. A significant challenge to obtaining the desired effect of NO is getting the correct concentrations of the drug for a specific exposure.
Previous attempts to incorporate NO into topical agents have been unsuccessful because the concentration varies greatly in a gel or cream formulation.
The NB Therapeutics patent estate covers the use of NO in gas form (gNO), allowing for precise regulation to achieve the desired effect.
NB Therapeutics’s primary goal with NO gas is for the use of gNO as an anti-infective, including Commercialization of gNO products for:
The company has completed Phase 2 clinical trials for the use of gNO in the treatment of moderate-to-severe tinea pedis and in Skin and Soft Tissue Infections (SSTI). Learn more about tinea pedis and SSTI.